drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01166 | DB08873 | 477 | 74 | [
"DDInter379",
"DDInter221"
] | Cilostazol | Boceprevir | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Major | 2 | [
[
[
477,
25,
74
]
],
[
[
477,
6,
8374
],
[
8374,
45,
74
]
],
[
[
477,
21,
28769
],
[
28769,
60,
74
]
],
[
[
477,
24,
1374
],
[
1374,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Boceprevir"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bocepre... | Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Boceprevir (Compound)
Cilostazol (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Abira... |
DB00365 | DB00888 | 839 | 1,001 | [
"DDInter842",
"DDInter1133"
] | Grepafloxacin | Mechlorethamine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Minor | 0 | [
[
[
839,
23,
1001
]
],
[
[
839,
23,
450
],
[
450,
1,
1001
]
],
[
[
839,
25,
126
],
[
126,
23,
1001
]
],
[
[
839,
25,
51
],
[
51,
24,... | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
... | Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can li... |
DB00405 | DB14575 | 128 | 733 | [
"DDInter517",
"DDInter674"
] | Dexbrompheniramine | Eslicarbazepine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
128,
24,
733
]
],
[
[
128,
24,
1264
],
[
1264,
24,
733
]
],
[
[
128,
74,
1594
],
[
1594,
24,
733
]
],
[
[
128,
63,
475
],
[
475,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepi... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate... |
DB01138 | DB12010 | 804 | 214 | [
"DDInter1726",
"DDInter785"
] | Sulfinpyrazone | Fostamatinib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
804,
24,
214
]
],
[
[
804,
24,
976
],
[
976,
24,
214
]
],
[
[
804,
63,
723
],
[
723,
24,
214
]
],
[
[
804,
62,
1144
],
[
1144,
2... | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
... | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitan... |
DB00092 | DB08879 | 58 | 632 | [
"DDInter40",
"DDInter173"
] | Alefacept | Belimumab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Moderate | 1 | [
[
[
58,
24,
632
]
],
[
[
58,
23,
1461
],
[
1461,
23,
632
]
],
[
[
58,
23,
1114
],
[
1114,
62,
632
]
],
[
[
58,
24,
713
],
[
713,
63,... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belimumab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"V... | Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Belimumab
Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate ma... |
DB00242 | DB13985 | 1,064 | 546 | [
"DDInter392",
"DDInter1108"
] | Cladribine | Lutetium Lu 177 dotatate | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Major | 2 | [
[
[
1064,
25,
546
]
],
[
[
1064,
64,
66
],
[
66,
24,
546
]
],
[
[
1064,
25,
1683
],
[
1683,
24,
546
]
],
[
[
1064,
24,
1613
],
[
1613,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efalizumab"
],
[
"Efalizumab"... | Cladribine may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Cladribine may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause... |
DB01324 | DB09135 | 178 | 1,211 | [
"DDInter1490",
"DDInter967"
] | Polythiazide | Ioxilan | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
178,
24,
1211
]
],
[
[
178,
1,
323
],
[
323,
24,
1211
]
],
[
[
178,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
178,
63,
1287
],
[
1287,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} ... | Polythiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate i... |
DB01156 | DB11642 | 593 | 938 | [
"DDInter252",
"DDInter1480"
] | Bupropion | Pitolisant | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Major | 2 | [
[
[
593,
25,
938
]
],
[
[
593,
64,
1133
],
[
1133,
24,
938
]
],
[
[
593,
25,
820
],
[
820,
24,
938
]
],
[
[
593,
62,
752
],
[
752,
2... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} m... | Bupropion may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Bupropion may lead to a major life threatening interaction when taken with Alimemazine and Alimemazine may cause a moderate in... |
DB01118 | DB11691 | 33 | 1,499 | [
"DDInter76",
"DDInter1258"
] | Amiodarone | Naldemedine | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
33,
24,
1499
]
],
[
[
33,
63,
723
],
[
723,
24,
1499
]
],
[
[
33,
25,
1670
],
[
1670,
24,
1499
]
],
[
[
33,
24,
1478
],
[
1478,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Amiodarone may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause... |
DB06168 | DB09331 | 1,531 | 745 | [
"DDInter281",
"DDInter478"
] | Canakinumab | Daratumumab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
1531,
24,
745
]
],
[
[
1531,
63,
139
],
[
139,
24,
745
]
],
[
[
1531,
24,
287
],
[
287,
63,
745
]
],
[
[
1531,
24,
1362
],
[
1362,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate... |
DB00065 | DB15091 | 581 | 676 | [
"DDInter923",
"DDInter1901"
] | Infliximab | Upadacitinib | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
581,
25,
676
]
],
[
[
581,
23,
1193
],
[
1193,
23,
676
]
],
[
[
581,
24,
1430
],
[
1430,
24,
676
]
],
[
[
581,
25,
248
],
[
248,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T an... |
DB00280 | DB00526 | 494 | 1,555 | [
"DDInter575",
"DDInter1355"
] | Disopyramide | Oxaliplatin | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
494,
25,
1555
]
],
[
[
494,
6,
8803
],
[
8803,
45,
1555
]
],
[
[
494,
25,
79
],
[
79,
24,
1555
]
],
[
[
494,
25,
1213
],
[
1213,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compound)",
"... | Disopyramide (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Oxaliplatin (Compound)
Disopyramide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Disopyramide may lead to a ... |
DB00705 | DB11921 | 441 | 1,019 | [
"DDInter496",
"DDInter492"
] | Delavirdine | Deflazacort | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
441,
25,
1019
]
],
[
[
441,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
441,
24,
761
],
[
761,
24,
1019
]
],
[
[
441,
25,
629
],
[
629,
... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucapari... | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxa... |
DB00445 | DB00685 | 322 | 1,299 | [
"DDInter655",
"DDInter1887"
] | Epirubicin | Trovafloxacin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Minor | 0 | [
[
[
322,
23,
1299
]
],
[
[
322,
24,
872
],
[
872,
40,
1299
]
],
[
[
322,
23,
1467
],
[
1467,
40,
1299
]
],
[
[
322,
33,
3199
],
[
3199,
... | [
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemifloxacin"
],
[... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Trovafloxacin (Compou... |
DB01155 | DB01168 | 872 | 1,053 | [
"DDInter813",
"DDInter1526"
] | Gemifloxacin | Procarbazine | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Minor | 0 | [
[
[
872,
23,
1053
]
],
[
[
872,
63,
848
],
[
848,
40,
1053
]
],
[
[
872,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
872,
40,
246
],
[
246,
... | [
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Procarbazine"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Gemifloxacin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Gemifloxacin (Compound) resembles Gatifl... |
DB00609 | DB11989 | 595 | 1,434 | [
"DDInter694",
"DDInter183"
] | Ethionamide | Benznidazole | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
595,
24,
1434
]
],
[
[
595,
24,
375
],
[
375,
24,
1434
]
],
[
[
595,
24,
148
],
[
148,
63,
1434
]
],
[
[
595,
63,
581
],
[
581,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00595 | DB01337 | 1,545 | 1,579 | [
"DDInter1374",
"DDInter1385"
] | Oxytetracycline | Pancuronium | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release. | Moderate | 1 | [
[
[
1545,
24,
1579
]
],
[
[
1545,
24,
1610
],
[
1610,
1,
1579
]
],
[
[
1545,
24,
544
],
[
544,
24,
1579
]
],
[
[
1545,
63,
1031
],
[
1031,... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pancuronium"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pancuronium (Compound)
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a modera... |
DB00679 | DB09080 | 684 | 144 | [
"DDInter1796",
"DDInter1331"
] | Thioridazine | Olodaterol | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
684,
24,
144
]
],
[
[
684,
25,
1011
],
[
1011,
24,
144
]
],
[
[
684,
64,
11
],
[
11,
24,
144
]
],
[
[
684,
24,
543
],
[
543,
24,... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingol... | Thioridazine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Thioridazine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate ... |
DB06077 | DB09268 | 879 | 1,662 | [
"DDInter1102",
"DDInter1464"
] | Lumateperone | Picosulfuric acid | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
879,
24,
1662
]
],
[
[
879,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
879,
63,
597
],
[
597,
24,
1662
]
],
[
[
879,
64,
1573
],
[
1573,
... | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]... | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Chlorampheni... |
DB00612 | DB01364 | 1,121 | 22 | [
"DDInter216",
"DDInter650"
] | Bisoprolol | Ephedrine | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1121,
24,
22
]
],
[
[
1121,
24,
1445
],
[
1445,
1,
22
]
],
[
[
1121,
6,
3576
],
[
3576,
45,
22
]
],
[
[
1121,
21,
28680
],
[
28680,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Bisoprolol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Ephedrine (Compound)
Bisoprolol (Compound) causes Rash (Side Effect) and Rash (Si... |
DB00468 | DB01035 | 1,424 | 1,401 | [
"DDInter1557",
"DDInter1524"
] | Quinine | Procainamide | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | A derivative of procaine with less CNS action. | Major | 2 | [
[
[
1424,
25,
1401
]
],
[
[
1424,
24,
1120
],
[
1120,
1,
1401
]
],
[
[
1424,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
1424,
21,
28658
],
[
2... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Proparacaine"
],
[
"Proparacaine... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Proparacaine and Proparacaine (Compound) resembles Procainamide (Compound)
Quinine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Quinine (Compound) causes Vomiting (Side Effect) and Vomiting (S... |
DB00377 | DB01218 | 1,494 | 1,493 | [
"DDInter1382",
"DDInter852"
] | Palonosetron | Halofantrine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1494,
25,
1493
]
],
[
[
1494,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
1494,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1494,
24,
479
],
[
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Palonosetron (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Palonosetron (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases w... |
DB00372 | DB00986 | 999 | 1,192 | [
"DDInter1793",
"DDInter834"
] | Thiethylperazine | Glycopyrronium | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
999,
24,
1192
]
],
[
[
999,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
999,
24,
262
],
[
262,
24,
1192
]
],
[
[
999,
24,
551
],
[
551,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Cli... |
DB00717 | DB08890 | 1,197 | 16 | [
"DDInter1312",
"DDInter1069"
] | Norethisterone | Linaclotide | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Moderate | 1 | [
[
[
1197,
24,
16
]
],
[
[
1197,
1,
566
],
[
566,
24,
16
]
],
[
[
1197,
40,
890
],
[
890,
24,
16
]
],
[
[
1197,
1,
566
],
[
566,
40,
... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linaclotide"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Levonorgestrel"
],
[
"Levonorgestrel",
"{u} ma... | Norethisterone (Compound) resembles Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Linaclotide
Norethisterone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00444 | DB14409 | 63 | 1,129 | [
"DDInter1765",
"DDInter867"
] | Teniposide | Human adenovirus e serotype 4 strain cl-68578 antigen | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
63,
24,
1129
]
],
[
[
63,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
63,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
63,
63,
134
],
[
134,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Teniposide may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Teniposide may cause a moderate interaction that could exacerbate diseases when take... |
DB00087 | DB11921 | 599 | 1,019 | [
"DDInter41",
"DDInter492"
] | Alemtuzumab | Deflazacort | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
599,
24,
1019
]
],
[
[
599,
24,
270
],
[
270,
63,
1019
]
],
[
[
599,
24,
914
],
[
914,
24,
1019
]
],
[
[
599,
63,
1184
],
[
1184,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and D... |
DB00980 | DB01211 | 969 | 609 | [
"DDInter1564",
"DDInter393"
] | Ramelteon | Clarithromycin | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
969,
24,
609
]
],
[
[
969,
6,
10215
],
[
10215,
45,
609
]
],
[
[
969,
21,
28691
],
[
28691,
60,
609
]
],
[
[
969,
63,
600
],
[
600,
... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Ramelteon",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compoun... | Ramelteon (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound)
Ramelteon (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Clarithromycin (Compound)
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Fluconazol... |
DB00619 | DB09237 | 1,419 | 1,586 | [
"DDInter909",
"DDInter1045"
] | Imatinib | Levamlodipine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1419,
24,
1586
]
],
[
[
1419,
24,
466
],
[
466,
62,
1586
]
],
[
[
1419,
24,
578
],
[
578,
23,
1586
]
],
[
[
1419,
63,
1648
],
[
1648,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticag... |
DB00196 | DB12161 | 600 | 730 | [
"DDInter743",
"DDInter512"
] | Fluconazole | Deutetrabenazine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
600,
24,
730
]
],
[
[
600,
23,
112
],
[
112,
23,
730
]
],
[
[
600,
24,
322
],
[
322,
24,
730
]
],
[
[
600,
63,
521
],
[
521,
24,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin ... |
DB06810 | DB11003 | 397 | 748 | [
"DDInter1484",
"DDInter100"
] | Plicamycin | Anthrax vaccine | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
397,
24,
748
]
],
[
[
397,
25,
676
],
[
676,
63,
748
]
],
[
[
397,
63,
1683
],
[
1683,
24,
748
]
],
[
[
397,
64,
1057
],
[
1057,
... | [
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upa... | Plicamycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab... |
DB00951 | DB01234 | 1,072 | 1,220 | [
"DDInter986",
"DDInter513"
] | Isoniazid | Dexamethasone | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Minor | 0 | [
[
[
1072,
23,
1220
]
],
[
[
1072,
62,
870
],
[
870,
1,
1220
]
],
[
[
1072,
62,
175
],
[
175,
40,
1220
]
],
[
[
1072,
24,
617
],
[
617,
... | [
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
],
[
... | Isoniazid may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Isoniazid may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexametha... |
DB00344 | DB00938 | 1,302 | 455 | [
"DDInter1543",
"DDInter1635"
] | Protriptyline | Salmeterol | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1302,
24,
455
]
],
[
[
1302,
24,
688
],
[
688,
63,
455
]
],
[
[
1302,
7,
8606
],
[
8606,
46,
455
]
],
[
[
1302,
21,
29024
],
[
29024,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Protriptyline (Compound) upregulates ALDOC (Gene) and ALDOC (Gene) is upregulated by Salmeterol (Compound)
Pr... |
DB08868 | DB11921 | 1,011 | 1,019 | [
"DDInter737",
"DDInter492"
] | Fingolimod | Deflazacort | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1011,
25,
1019
]
],
[
[
1011,
25,
270
],
[
270,
63,
1019
]
],
[
[
1011,
24,
200
],
[
200,
24,
1019
]
],
[
[
1011,
64,
699
],
[
699,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u... | Fingolimod may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albi... |
DB00816 | DB08864 | 1,674 | 786 | [
"DDInter1346",
"DDInter1595"
] | Orciprenaline | Rilpivirine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1674,
24,
786
]
],
[
[
1674,
21,
28698
],
[
28698,
60,
786
]
],
[
[
1674,
24,
918
],
[
918,
24,
786
]
],
[
[
1674,
63,
51
],
[
51,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is... | Orciprenaline (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Rilpivirine (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01129 | DB01602 | 379 | 339 | [
"DDInter1559",
"DDInter159"
] | Rabeprazole | Bacampicillin | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal ac... | Moderate | 1 | [
[
[
379,
24,
339
]
],
[
[
379,
40,
837
],
[
837,
24,
339
]
],
[
[
379,
1,
1215
],
[
1215,
24,
339
]
],
[
[
379,
63,
126
],
[
126,
24... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacampicillin"
]
],
[
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause ... | Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bacampicillin
Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00598 | DB08816 | 1,523 | 578 | [
"DDInter1013",
"DDInter1802"
] | Labetalol | Ticagrelor | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Minor | 0 | [
[
[
1523,
23,
578
]
],
[
[
1523,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1523,
40,
271
],
[
271,
62,
578
]
],
[
[
1523,
25,
1011
],
[
1011,... | [
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by ... | Labetalol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Labetalol (Compound) resembles Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Labetalol may lead to a major life threatening int... |
DB00461 | DB01276 | 598 | 123 | [
"DDInter1254",
"DDInter706"
] | Nabumetone | Exenatide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
598,
24,
123
]
],
[
[
598,
24,
1573
],
[
1573,
24,
123
]
],
[
[
598,
63,
1560
],
[
1560,
24,
123
]
],
[
[
598,
24,
850
],
[
850,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegas... |
DB06603 | DB12332 | 39 | 1,619 | [
"DDInter1387",
"DDInter1626"
] | Panobinostat | Rucaparib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
39,
25,
1619
]
],
[
[
39,
63,
307
],
[
307,
23,
1619
]
],
[
[
39,
62,
112
],
[
112,
23,
1619
]
],
[
[
39,
63,
259
],
[
259,
24,
... | [
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafini... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metron... |
DB01041 | DB09237 | 770 | 1,586 | [
"DDInter1789",
"DDInter1045"
] | Thalidomide | Levamlodipine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
770,
24,
1586
]
],
[
[
770,
64,
1648
],
[
1648,
24,
1586
]
],
[
[
770,
24,
478
],
[
478,
24,
1586
]
],
[
[
770,
24,
1297
],
[
1297,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Alde... | Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may c... |
DB00108 | DB09036 | 1,066 | 812 | [
"DDInter1268",
"DDInter1668"
] | Natalizumab | Siltuximab | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
1066,
25,
812
]
],
[
[
1066,
23,
1193
],
[
1193,
62,
812
]
],
[
[
1066,
23,
1461
],
[
1461,
23,
812
]
],
[
[
1066,
25,
287
],
[
287,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Natalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Natalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB00224 | DB11581 | 215 | 1,456 | [
"DDInter917",
"DDInter1926"
] | Indinavir | Venetoclax | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
215,
25,
1456
]
],
[
[
215,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
215,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
215,
24,
466
],
[
466,
... | [
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Indinavir may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Indinavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interactio... |
DB01200 | DB12267 | 469 | 1,476 | [
"DDInter243",
"DDInter233"
] | Bromocriptine | Brigatinib | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
469,
24,
1476
]
],
[
[
469,
63,
629
],
[
629,
24,
1476
]
],
[
[
469,
40,
628
],
[
628,
24,
1476
]
],
[
[
469,
62,
888
],
[
888,
... | [
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Bromocriptine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
... | Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Bromocriptine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that... |
DB00909 | DB04868 | 306 | 478 | [
"DDInter1971",
"DDInter1293"
] | Zonisamide | Nilotinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
306,
24,
478
]
],
[
[
306,
6,
15724
],
[
15724,
45,
478
]
],
[
[
306,
21,
28963
],
[
28963,
60,
478
]
],
[
[
306,
24,
1040
],
[
1040,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Zonisamide",
"{u} (Compound) binds {v} (Gene)",
"CA7"
],
[
"CA7",
"{u} (Gene) is bound by {v} (Compound)",
... | Zonisamide (Compound) binds CA7 (Gene) and CA7 (Gene) is bound by Nilotinib (Compound)
Zonisamide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may c... |
DB00252 | DB01254 | 362 | 1,213 | [
"DDInter1460",
"DDInter484"
] | Phenytoin | Dasatinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
362,
25,
1213
]
],
[
[
362,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
362,
7,
6952
],
[
6952,
46,
1213
]
],
[
[
362,
18,
6495
],
[
6495,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
... | Phenytoin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Phenytoin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Dasatinib (Compound)
Phenytoin (Compound) downregulates S100A6 (Gene) and S100A6 (Gene) is downregulated by Dasatinib (Compound)
Phenytoin (Compoun... |
DB01064 | DB01255 | 1,148 | 633 | [
"DDInter987",
"DDInter1078"
] | Isoprenaline | Lisdexamfetamine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
1148,
24,
633
]
],
[
[
1148,
63,
551
],
[
551,
1,
633
]
],
[
[
1148,
63,
80
],
[
80,
40,
633
]
],
[
[
1148,
24,
1529
],
[
1529,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfe... |
DB00006 | DB01240 | 942 | 885 | [
"DDInter217",
"DDInter657"
] | Bivalirudin | Epoprostenol | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
942,
24,
885
]
],
[
[
942,
24,
1061
],
[
1061,
1,
885
]
],
[
[
942,
23,
539
],
[
539,
62,
885
]
],
[
[
942,
24,
1512
],
[
1512,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can li... |
DB00749 | DB00877 | 59 | 629 | [
"DDInter699",
"DDInter1678"
] | Etodolac | Sirolimus | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
59,
25,
629
]
],
[
[
59,
7,
3727
],
[
3727,
46,
629
]
],
[
[
59,
21,
28898
],
[
28898,
60,
629
]
],
[
[
59,
63,
167
],
[
167,
24... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Etodolac",
"{u} (Compound) upregulates {v} (Gene)",
"MAL"
],
[
"MAL",
"{u} (Gene) is upregulated by {v} (Compound)",
"Siroli... | Etodolac (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Sirolimus (Compound)
Etodolac (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone ... |
DB00169 | DB00252 | 386 | 362 | [
"DDInter367",
"DDInter1460"
] | Cholecalciferol | Phenytoin | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Moderate | 1 | [
[
[
386,
24,
362
]
],
[
[
386,
24,
759
],
[
759,
40,
362
]
],
[
[
386,
6,
3486
],
[
3486,
45,
362
]
],
[
[
386,
25,
1196
],
[
1196,
... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenytoin (Compound)
Cholecalciferol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenytoin (Compound)
Cholecalciferol may lead to a major life threatening interac... |
DB00999 | DB01143 | 504 | 923 | [
"DDInter883",
"DDInter65"
] | Hydrochlorothiazide | Amifostine | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
504,
24,
923
]
],
[
[
504,
21,
28642
],
[
28642,
60,
923
]
],
[
[
504,
1,
359
],
[
359,
24,
923
]
],
[
[
504,
40,
178
],
[
178,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effec... | Hydrochlorothiazide (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Hydrochlorothiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Hydrochlorothiazide (Compo... |
DB00519 | DB00912 | 1,638 | 473 | [
"DDInter1843",
"DDInter1581"
] | Trandolapril | Repaglinide | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1638,
24,
473
]
],
[
[
1638,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1638,
24,
1512
],
[
1512,
24,
473
]
],
[
[
1638,
63,
1645
],
[
164... | [
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Trandolapril",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effe... | Trandolapril (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00092 | DB14409 | 58 | 1,129 | [
"DDInter40",
"DDInter867"
] | Alefacept | Human adenovirus e serotype 4 strain cl-68578 antigen | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
58,
24,
1129
]
],
[
[
58,
63,
1057
],
[
1057,
24,
1129
]
],
[
[
58,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
58,
25,
1259
],
[
1259,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Alefacept may cause a moderate interaction that could exacerbate disea... |
DB06274 | DB11901 | 574 | 913 | [
"DDInter59",
"DDInter107"
] | Alvimopan | Apalutamide | Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
574,
24,
913
]
],
[
[
574,
1,
935
],
[
935,
24,
913
]
],
[
[
574,
64,
475
],
[
475,
24,
913
]
],
[
[
574,
64,
704
],
[
704,
25,
... | [
[
[
"Alvimopan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Alvimopan",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a moderate... | Alvimopan (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Alvimopan may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases... |
DB00073 | DB01610 | 1,394 | 248 | [
"DDInter1608",
"DDInter1912"
] | Rituximab | Valganciclovir | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1394,
24,
248
]
],
[
[
1394,
24,
563
],
[
563,
1,
248
]
],
[
[
1394,
25,
507
],
[
507,
63,
248
]
],
[
[
1394,
24,
738
],
[
738,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Rituximab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate... |
DB01159 | DB09472 | 419 | 1,383 | [
"DDInter854",
"DDInter1693"
] | Halothane | Sodium sulfate | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
419,
24,
1383
]
],
[
[
419,
24,
609
],
[
609,
24,
1383
]
],
[
[
419,
63,
521
],
[
521,
24,
1383
]
],
[
[
419,
25,
1618
],
[
1618,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Goserelin a... |
DB00637 | DB11652 | 1,557 | 1,155 | [
"DDInter128",
"DDInter1891"
] | Astemizole | Tucatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1557,
24,
1155
]
],
[
[
1557,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1557,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
1557,
24,
659
],
[
659... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Astemizole may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderat... |
DB00280 | DB11978 | 494 | 124 | [
"DDInter575",
"DDInter822"
] | Disopyramide | Glasdegib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Major | 2 | [
[
[
494,
25,
124
]
],
[
[
494,
23,
112
],
[
112,
23,
124
]
],
[
[
494,
25,
79
],
[
79,
24,
124
]
],
[
[
494,
24,
688
],
[
688,
24,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Disopyramide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cau... |
DB00708 | DB11730 | 1,454 | 351 | [
"DDInter1718",
"DDInter1588"
] | Sufentanil | Ribociclib | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
1454,
24,
351
]
],
[
[
1454,
25,
222
],
[
222,
23,
351
]
],
[
[
1454,
24,
1532
],
[
1532,
24,
351
]
],
[
[
1454,
64,
267
],
[
267,
... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Sufentanil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Sufentanil may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause ... |
DB00902 | DB01377 | 104 | 1,283 | [
"DDInter1168",
"DDInter1119"
] | Methdilazine | Magnesium oxide | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
104,
23,
1283
]
],
[
[
104,
63,
743
],
[
743,
23,
1283
]
],
[
[
104,
75,
684
],
[
684,
23,
1283
]
],
[
[
104,
74,
216
],
[
216,
... | [
[
[
"Methdilazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Lisinopril and Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Methdilazine (Compound) resembles Thioridazine (Compound) and Methdilazine may lead to a major life threate... |
DB09054 | DB09083 | 384 | 880 | [
"DDInter905",
"DDInter996"
] | Idelalisib | Ivabradine | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
384,
25,
880
]
],
[
[
384,
64,
1478
],
[
1478,
24,
880
]
],
[
[
384,
25,
159
],
[
159,
63,
880
]
],
[
[
384,
63,
1040
],
[
1040,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may... | Idelalisib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Idelalisib may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate ... |
DB00471 | DB09098 | 201 | 98 | [
"DDInter1242",
"DDInter1700"
] | Montelukast | Somatrem | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
201,
24,
98
]
],
[
[
201,
24,
159
],
[
159,
63,
98
]
],
[
[
201,
24,
11
],
[
11,
24,
98
]
],
[
[
201,
63,
188
],
[
188,
24,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[... | Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and ... |
DB00250 | DB00834 | 10 | 932 | [
"DDInter475",
"DDInter1215"
] | Dapsone | Mifepristone | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
10,
24,
932
]
],
[
[
10,
6,
7524
],
[
7524,
45,
932
]
],
[
[
10,
21,
28762
],
[
28762,
60,
932
]
],
[
[
10,
24,
112
],
[
112,
62... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Mifepristone (Compound)
Dapsone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronid... |
DB00238 | DB12332 | 188 | 1,619 | [
"DDInter1285",
"DDInter1626"
] | Nevirapine | Rucaparib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
188,
24,
1619
]
],
[
[
188,
24,
222
],
[
222,
23,
1619
]
],
[
[
188,
24,
309
],
[
309,
24,
1619
]
],
[
[
188,
25,
1019
],
[
1019,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabep... |
DB00951 | DB14723 | 1,072 | 159 | [
"DDInter986",
"DDInter1026"
] | Isoniazid | Larotrectinib | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1072,
24,
159
]
],
[
[
1072,
23,
1135
],
[
1135,
23,
159
]
],
[
[
1072,
63,
63
],
[
63,
24,
159
]
],
[
[
1072,
24,
951
],
[
951,
... | [
[
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Isoniazid may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide ... |
DB00662 | DB11186 | 717 | 1,609 | [
"DDInter1873",
"DDInter1427"
] | Trimethobenzamide | Pentoxyverine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
717,
24,
1609
]
],
[
[
717,
24,
314
],
[
314,
24,
1609
]
],
[
[
717,
63,
556
],
[
556,
24,
1609
]
],
[
[
717,
24,
418
],
[
418,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Valp... |
DB00005 | DB06595 | 1,057 | 1,491 | [
"DDInter687",
"DDInter1214"
] | Etanercept | Midostaurin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
1057,
25,
1491
]
],
[
[
1057,
24,
112
],
[
112,
23,
1491
]
],
[
[
1057,
24,
289
],
[
289,
24,
1491
]
],
[
[
1057,
25,
270
],
[
270,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metron... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and... |
DB00361 | DB14004 | 134 | 398 | [
"DDInter1939",
"DDInter1806"
] | Vinorelbine | Tildrakizumab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
134,
24,
398
]
],
[
[
134,
63,
1461
],
[
1461,
23,
398
]
],
[
[
134,
63,
58
],
[
58,
24,
398
]
],
[
[
134,
24,
200
],
[
200,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefac... |
DB01224 | DB11979 | 623 | 1,320 | [
"DDInter1553",
"DDInter625"
] | Quetiapine | Elagolix | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
623,
24,
1320
]
],
[
[
623,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
623,
63,
79
],
[
79,
24,
1320
]
],
[
[
623,
25,
129
],
[
129,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Soraf... |
DB01129 | DB13257 | 379 | 260 | [
"DDInter1559",
"DDInter727"
] | Rabeprazole | Ferrous sulfate anhydrous | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
379,
24,
260
]
],
[
[
379,
40,
837
],
[
837,
24,
260
]
],
[
[
379,
63,
542
],
[
542,
24,
260
]
],
[
[
379,
24,
1231
],
[
1231,
2... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u... | Rabeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine may cause a mode... |
DB00289 | DB11837 | 847 | 1,297 | [
"DDInter132",
"DDInter1351"
] | Atomoxetine | Osilodrostat | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
847,
24,
1297
]
],
[
[
847,
23,
112
],
[
112,
23,
1297
]
],
[
[
847,
24,
401
],
[
401,
24,
1297
]
],
[
[
847,
40,
307
],
[
307,
... | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine an... |
DB00562 | DB09020 | 1,014 | 28 | [
"DDInter188",
"DDInter212"
] | Benzthiazide | Bisacodyl | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
1014,
24,
28
]
],
[
[
1014,
24,
870
],
[
870,
24,
28
]
],
[
[
1014,
40,
674
],
[
674,
24,
28
]
],
[
[
1014,
25,
1166
],
[
1166,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a mo... |
DB09280 | DB12329 | 1,604 | 464 | [
"DDInter1101",
"DDInter660"
] | Lumacaftor | Eravacycline | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquin... | Major | 2 | [
[
[
1604,
25,
464
]
],
[
[
1604,
63,
1517
],
[
1517,
25,
464
]
],
[
[
1604,
63,
479
],
[
479,
23,
609
],
[
609,
23,
464
]
],
[
[
1604,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eravacycline"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
[
"Isotre... | Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Eravacycline
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may ca... |
DB00026 | DB00683 | 1,184 | 1,382 | [
"DDInter94",
"DDInter1212"
] | Anakinra | Midazolam | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Moderate | 1 | [
[
[
1184,
24,
1382
]
],
[
[
1184,
24,
902
],
[
902,
40,
1382
]
],
[
[
1184,
24,
1573
],
[
1573,
23,
1382
]
],
[
[
1184,
24,
1220
],
[
1220... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midazolam"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"Cl... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Midazolam (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinica... |
DB00619 | DB15233 | 1,419 | 1,650 | [
"DDInter909",
"DDInter142"
] | Imatinib | Avapritinib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1419,
25,
1650
]
],
[
[
1419,
25,
1478
],
[
1478,
24,
1650
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
1650
]
],
[
[
1419,
63,
1257
],
[
12... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may ca... | Imatinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moder... |
DB00349 | DB01211 | 902 | 609 | [
"DDInter401",
"DDInter393"
] | Clobazam | Clarithromycin | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
902,
24,
609
]
],
[
[
902,
6,
4973
],
[
4973,
45,
609
]
],
[
[
902,
21,
28662
],
[
28662,
60,
609
]
],
[
[
902,
63,
600
],
[
600,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Clobazam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clobazam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Clobazam (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazo... |
DB01149 | DB08880 | 851 | 1,510 | [
"DDInter1274",
"DDInter1771"
] | Nefazodone | Teriflunomide | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
851,
25,
1510
]
],
[
[
851,
63,
608
],
[
608,
23,
1510
]
],
[
[
851,
24,
129
],
[
129,
63,
1510
]
],
[
[
851,
25,
1406
],
[
1406,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocain... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzal... |
DB00372 | DB06702 | 999 | 573 | [
"DDInter1793",
"DDInter731"
] | Thiethylperazine | Fesoterodine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
999,
24,
573
]
],
[
[
999,
24,
211
],
[
211,
1,
573
]
],
[
[
999,
63,
494
],
[
494,
1,
573
]
],
[
[
999,
24,
100
],
[
100,
24,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fe... |
DB00294 | DB05679 | 1,336 | 1,683 | [
"DDInter701",
"DDInter1907"
] | Etonogestrel | Ustekinumab | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1336,
24,
1683
]
],
[
[
1336,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
1336,
24,
478
],
[
478,
24,
1683
]
],
[
[
1336,
25,
1101
],
[
1101... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Niloti... |
DB00938 | DB12010 | 455 | 214 | [
"DDInter1635",
"DDInter785"
] | Salmeterol | Fostamatinib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
455,
24,
214
]
],
[
[
455,
63,
51
],
[
51,
24,
214
]
],
[
[
455,
62,
1573
],
[
1573,
24,
214
]
],
[
[
455,
24,
924
],
[
924,
24,... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Prednisone and Pr... |
DB00486 | DB00780 | 1,614 | 551 | [
"DDInter1253",
"DDInter1440"
] | Nabilone | Phenelzine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
1614,
24,
551
]
],
[
[
1614,
24,
94
],
[
94,
40,
551
]
],
[
[
1614,
21,
28827
],
[
28827,
60,
551
]
],
[
[
1614,
63,
999
],
[
999,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Phenelzine (Compound)
Nabilone (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Phenelzine (Compound)
Nabilone may cause... |
DB00445 | DB08868 | 322 | 1,011 | [
"DDInter655",
"DDInter737"
] | Epirubicin | Fingolimod | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
322,
25,
1011
]
],
[
[
322,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
322,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
322,
24,
144
],
[
144,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by... | Epirubicin (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when ... |
DB00812 | DB11817 | 998 | 1,259 | [
"DDInter1451",
"DDInter165"
] | Phenylbutazone | Baricitinib | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Moderate | 1 | [
[
[
998,
24,
1259
]
],
[
[
998,
63,
1274
],
[
1274,
24,
1259
]
],
[
[
998,
24,
927
],
[
927,
24,
1259
]
],
[
[
998,
40,
576
],
[
576,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
... | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafe... |
DB00559 | DB09038 | 152 | 1,450 | [
"DDInter223",
"DDInter636"
] | Bosentan | Empagliflozin | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
152,
24,
1450
]
],
[
[
152,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
152,
63,
245
],
[
245,
24,
1450
]
],
[
[
152,
25,
1017
],
[
1017,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Glimep... |
DB01009 | DB01362 | 935 | 497 | [
"DDInter1009",
"DDInter960"
] | Ketoprofen | Iohexol | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
935,
25,
497
]
],
[
[
935,
25,
258
],
[
258,
40,
497
]
],
[
[
935,
7,
5727
],
[
5727,
46,
497
]
],
[
[
935,
21,
28681
],
[
28681,
... | [
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Ketoprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Compo... | Ketoprofen may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Ketoprofen (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Iohexol (Compound)
Ketoprofen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity ... |
DB00047 | DB09389 | 176 | 517 | [
"DDInter932",
"DDInter1315"
] | Insulin glargine | Norgestrel | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
176,
24,
517
]
],
[
[
176,
24,
1130
],
[
1130,
23,
517
]
],
[
[
176,
24,
52
],
[
52,
24,
517
]
],
[
[
176,
63,
305
],
[
305,
24,... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglu... |
DB04953 | DB06663 | 495 | 1,154 | [
"DDInter708",
"DDInter1398"
] | Ezogabine | Pasireotide | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
495,
25,
1154
]
],
[
[
495,
21,
28898
],
[
28898,
60,
1154
]
],
[
[
495,
62,
112
],
[
112,
23,
1154
]
],
[
[
495,
24,
1662
],
[
1662,
... | [
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Ezogabine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} ... | Ezogabine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pasireotide (Compound)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB00758 | DB09068 | 1,347 | 1,427 | [
"DDInter413",
"DDInter1948"
] | Clopidogrel | Vortioxetine | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1347,
24,
1427
]
],
[
[
1347,
63,
25
],
[
25,
24,
1427
]
],
[
[
1347,
36,
256
],
[
256,
24,
1427
]
],
[
[
1347,
24,
477
],
[
477,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Clopidogrel (Compound) resembles Prasugrel (Compound) and Clopidogrel may lead to a major life threatenin... |
DB00348 | DB00661 | 254 | 122 | [
"DDInter1300",
"DDInter1928"
] | Nitisinone | Verapamil | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
254,
24,
122
]
],
[
[
254,
21,
28809
],
[
28809,
60,
122
]
],
[
[
254,
63,
1101
],
[
1101,
23,
122
]
],
[
[
254,
24,
1512
],
[
1512,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cause... | Nitisinone (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Verapamil (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Verapamil
... |
DB08934 | DB12010 | 1,200 | 214 | [
"DDInter1695",
"DDInter785"
] | Sofosbuvir | Fostamatinib | Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 bein... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1200,
24,
214
]
],
[
[
1200,
25,
1017
],
[
1017,
63,
214
]
],
[
[
1200,
63,
126
],
[
126,
24,
214
]
],
[
[
1200,
64,
129
],
[
129,
... | [
[
[
"Sofosbuvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Sofosbuvir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatin... | Sofosbuvir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Sofosbuvir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a ... |
DB00598 | DB01168 | 1,523 | 1,053 | [
"DDInter1013",
"DDInter1526"
] | Labetalol | Procarbazine | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
1523,
24,
1053
]
],
[
[
1523,
24,
848
],
[
848,
40,
1053
]
],
[
[
1523,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
1523,
23,
126
],
[
126... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Labetalol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Labetalol may cause a minor interaction that c... |
DB00861 | DB01225 | 914 | 500 | [
"DDInter551",
"DDInter645"
] | Diflunisal | Enoxaparin | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
914,
25,
500
]
],
[
[
914,
21,
28778
],
[
28778,
60,
500
]
],
[
[
914,
24,
1074
],
[
1074,
63,
500
]
],
[
[
914,
24,
1039
],
[
1039,
... | [
[
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Diflunisal",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is c... | Diflunisal (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Enoxaparin (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases w... |
DB01067 | DB08820 | 959 | 1,478 | [
"DDInter826",
"DDInter997"
] | Glipizide | Ivacaftor | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
959,
24,
1478
]
],
[
[
959,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
959,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
959,
24,
318
],
[
318,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Glipizide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalop... |
DB00425 | DB00501 | 558 | 752 | [
"DDInter1970",
"DDInter380"
] | Zolpidem | Cimetidine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Moderate | 1 | [
[
[
558,
24,
752
]
],
[
[
558,
6,
21998
],
[
21998,
45,
752
]
],
[
[
558,
21,
29134
],
[
29134,
60,
752
]
],
[
[
558,
24,
609
],
[
609,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by {v... | Zolpidem (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Cimetidine (Compound)
Zolpidem (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Cimetidine (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clari... |
DB00741 | DB01125 | 167 | 279 | [
"DDInter885",
"DDInter98"
] | Hydrocortisone | Anisindione | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
167,
24,
279
]
],
[
[
167,
63,
1647
],
[
1647,
23,
279
]
],
[
[
167,
24,
913
],
[
913,
63,
279
]
],
[
[
167,
1,
175
],
[
175,
24... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Anisindione
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Ap... |
DB00888 | DB08868 | 1,001 | 1,011 | [
"DDInter1133",
"DDInter737"
] | Mechlorethamine | Fingolimod | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1001,
25,
1011
]
],
[
[
1001,
21,
29563
],
[
29563,
60,
1011
]
],
[
[
1001,
24,
748
],
[
748,
63,
1011
]
],
[
[
1001,
24,
1136
],
[
11... | [
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) causes {v} (Side Effect)",
"Lymphopenia"
],
[
"Lymphopenia",
"{u} (Side Effect) is cause... | Mechlorethamine (Compound) causes Lymphopenia (Side Effect) and Lymphopenia (Side Effect) is caused by Fingolimod (Compound)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases... |
DB00883 | DB01156 | 426 | 593 | [
"DDInter989",
"DDInter252"
] | Isosorbide dinitrate | Bupropion | A vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
426,
24,
593
]
],
[
[
426,
6,
8374
],
[
8374,
45,
593
]
],
[
[
426,
18,
7359
],
[
7359,
57,
593
]
],
[
[
426,
21,
29005
],
[
29005,
... | [
[
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Isosorbide dinitrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound ... | Isosorbide dinitrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Isosorbide dinitrate (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Bupropion (Compound)
Isosorbide dinitrate (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfolia... |
DB00365 | DB01234 | 839 | 1,220 | [
"DDInter842",
"DDInter513"
] | Grepafloxacin | Dexamethasone | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
839,
25,
1220
]
],
[
[
839,
25,
870
],
[
870,
1,
1220
]
],
[
[
839,
25,
175
],
[
175,
40,
1220
]
],
[
[
839,
24,
617
],
[
617,
4... | [
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocorti... | Grepafloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Grepafloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Gr... |
DB01236 | DB08865 | 679 | 1,593 | [
"DDInter1664",
"DDInter448"
] | Sevoflurane | Crizotinib | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
679,
25,
1593
]
],
[
[
679,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
679,
21,
28771
],
[
28771,
60,
1593
]
],
[
[
679,
24,
286
],
[
286,
... | [
[
[
"Sevoflurane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Sevoflurane",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizo... | Sevoflurane (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Sevoflurane (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Sevoflurane may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00554 | DB00945 | 1,027 | 1,479 | [
"DDInter1478",
"DDInter20"
] | Piroxicam | Acetylsalicylic acid | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
1027,
24,
1479
]
],
[
[
1027,
6,
6017
],
[
6017,
45,
1479
]
],
[
[
1027,
10,
11666
],
[
11666,
49,
1479
]
],
[
[
1027,
54,
19122
],
[
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Com... | Piroxicam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Acetylsalicylic acid (Compound)
Piroxicam (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Acetylsalicylic acid (Compound)
Piroxicam (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharma... |
DB01136 | DB09039 | 772 | 1,670 | [
"DDInter305",
"DDInter629"
] | Carvedilol | Eliglustat | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
772,
24,
1670
]
],
[
[
772,
24,
1499
],
[
1499,
63,
1670
]
],
[
[
772,
25,
119
],
[
119,
63,
1670
]
],
[
[
772,
24,
478
],
[
478,
... | [
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Carvedilol may lead to a major life threatening interaction when taken with Talazoparib and Talazoparib may ca... |
DB00688 | DB09278 | 955 | 852 | [
"DDInter1251",
"DDInter24"
] | Mycophenolate mofetil | Activated charcoal | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Major | 2 | [
[
[
955,
25,
852
]
],
[
[
955,
63,
964
],
[
964,
24,
852
]
],
[
[
955,
24,
1620
],
[
1620,
24,
852
]
],
[
[
955,
25,
1377
],
[
1377,
... | [
[
[
"Mycophenolate mofetil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Activated charcoal"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.